ClinicalTrials.gg
Active, not recruitingNCT04540692NEOSAMBAUpdated Sep 2, 2026

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

A Phase 3 interventional study of Docetaxel or Paclitaxel and Cyclophosphamide + Doxorrubicin in Breast Cancer, sponsored by Latin American Cooperative Oncology Group. Active, not recruiting at 16 sites in Brazil. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Latin American Cooperative Oncology Group · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.

Enrollment
116th of 309
446 · median 250
Started
2021
with 26 others
Phase 3
143 of 351
22 open now
Primary completion
2027-04
later than 59 of 110 live
Registered
221st of 351
by date
Lead sponsor
7 of 351
Latin American Cooperative Oncology Group

Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 116th largest by enrollment of the 309 interventional ones that give a count, is one of 27 that started in 2021, is one of 143 in phase 3, reaches primary completion later than 59 of the 110 other live ones, and was the 221st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Breast Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.

Read the detailed description

Multicenter, phase III, open-label, randomized clinical trial, which will include 494 patients randomized to two neoadjuvant chemotherapy arms. The treatment protocol will be the same in both groups, only the regimens sequences will be evaluated: starting with anthracycline versus taxane, with or without carboplatin for patients with triple negative subtype. The chemotherapy regimen will follow the institution's routine, which includes the use of CA in the anthracyclical phase and, in the taxane phase, the use of docetaxel every 21 days or weekly paclitaxel. The rest of the treatment (surgery, radiotherapy, hormone therapy) will not be part of the study and will be carried out according to institutional guidelines.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants, with at least 18 years old on the day of signing the free and ;
  • Invasive breast carcinoma stage III (RH positive) or IIB/III (RH negative), according to TNM 8th edition; confirmed diagnosis of invasive breast carcinoma (with any histology), negative;
  • The participant (or legally acceptable representative, if applicable) provides written informed consent for the study;
  • The participant must agree to use a as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of the study treatment;
  • Have a functional capacity according to the (ECOG) from 0 to 2. The evaluation of the ECOG must be carried out within 7 days before the inclusion date.
  • Have adequate organic function. The samples must be collected within 60 days before the start of the study treatment;
  • Have adequate cardiac function as assessed by echocardiogram or performed up to 60 days before the start of treatment under study.

Exclusion criteria

Exclusion Criteria:

- Individuals who do not meet the inclusion criteria above-mentioned.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
446 participants (actual)

Study arms

  • Active comparator
    Start with Cyclophosphamide + Doxorrubicin

    Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.

    Drug: Cyclophosphamide + Doxorrubicin

  • Experimental
    Start with Docetaxel or Paclitaxel

    Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.

    Drug: Docetaxel or Paclitaxel

Interventions

  • DrugDocetaxel or Paclitaxel

    Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks

    Also known as: Taxotere or Taxol

  • DrugCyclophosphamide + Doxorrubicin

    Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles

    Also known as: Citoxan + Rubidox

06

What researchers measure

Primary outcomes

  1. Invasive disease-free survival (IDFS)

    Defined as the time elapsed between the date of randomization and the date of invasive recurrence (excludes carcinoma in situ) or death, whichever comes first..

    Time frame: An average of 8 years

07

Study locations

16 sites
  • Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
    Cachoeiro de Itapemirim, Espírito Santo 29.308-065, Brazil
  • Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel
    Salvador, Estado de Bahia 400.50-410, Brazil
  • Centro de Pesquisa do Hospital Araújo Jorge
    Goiânia, Goiás 74.605-010, Brazil
  • ICTR - Instituto do Câncer e Transplante de Curitiba
    Curitiba, Paraná 80.510-130, Brazil
  • HUEM/CEON - Hospital Universitário Evangélico Mackenzie
    Curitiba, Paraná 80.730-150, Brazil
  • Hospital Erasto Gaertner
    Curitiba, Paraná 81.520-060, Brazil
  • IMIP - Instituto de Medicina Integral Professor Fernando Figueira
    Recife, Pernambuco 50.070-902, Brazil
  • INCA - Instituto Nacional de Câncer
    Rio de Janeiro, Rio de Janeiro 20.230-130, Brazil
  • HFOA - Hospital da Fundação Oswaldo Aranha
    Volta Redonda, Rio de Janeiro 27.251-260, Brazil
  • HCPA - Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90.035-903, Brazil
  • CEPON - Centro de Pesquisas Oncológicas
    Florianópolis, Santa Catarina 88.034-000, Brazil
  • Hospital de Amor de Barretos
    Barretos, São Paulo 14.784-400, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista (UPECLIN)
    Botucatu, São Paulo 18.618-686, Brazil
  • Faculdade de Ciências Médicas da Unicamp
    Campinas, São Paulo 13.083-881, Brazil
  • Hospital de Amor Jales - Hospital de Câncer de Barretos
    Jales, São Paulo 15.706-396, Brazil
  • IBCC Oncologia - Núcleo de Pesquisa São Camilo
    São Paulo, São Paulo 04.014-002, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Apr 2027, 75 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 75 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Sep 7, 2020
StartActual
Jan 12, 2021
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2030
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04540692
Lead sponsor
Latin American Cooperative Oncology Group
Collaborators
Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Jan 12, 2021
Primary completion
Apr 2027 (estimated)
Completion
Oct 2030 (estimated)
Last update
Sep 2, 2026

Study contacts

José Bines
principal investigator · Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion